Berdazimer Gel 10.3% is the Preferred First-Line Treatment for Molluscum Contagiosum
For treating molluscum contagiosum, berdazimer gel 10.3% should be your first choice over cantharidin, as it is the only FDA-approved topical prescription medication for this indication with proven efficacy in large randomized controlled trials and can be applied at home by patients. 1
Why Berdazimer Gel 10.3% is Superior
FDA Approval and Evidence Base
Berdazimer gel 10.3% (brand name ZELSUVMI) is FDA-approved specifically for molluscum contagiosum in patients ≥1 year of age 1. This approval is based on three large, double-blind, vehicle-controlled randomized trials involving 1,598 patients, demonstrating:
- Complete clearance rate of 30-32.4% at 12 weeks versus 19.7-19.8% with vehicle (odds ratio 1.75-2.0, P<0.001) 2, 3
- Consistent efficacy across all age groups, lesion counts, and disease durations 2
- Early clearance: 14.4% of patients discontinued treatment due to MC clearance by week 12 3
At-Home Application Advantage
Unlike cantharidin which requires in-office application by a healthcare provider, berdazimer gel is applied once daily at home by the patient or caregiver 1. This provides:
- Greater convenience and reduced healthcare visits
- Continuous treatment without scheduling delays
- Lower overall healthcare costs
Safety Profile
The most common adverse effects are application-site reactions (mostly mild-to-moderate):
- Pain/burning/stinging: 18.7% (vs 4.8% vehicle) 2
- Erythema: 11.7% (vs 1.3% vehicle) 2
- Pruritus, exfoliation, dermatitis 1, 3
Critical safety instruction: Discontinue if pain, pruritus, swelling, or erythema persists >24 hours after application, as this may indicate allergic contact dermatitis 1.
Why Cantharidin is Second-Line
Limited Evidence Quality
While cantharidin has been used for decades, the evidence base is substantially weaker:
- Only one small randomized controlled trial (n=29 patients) showed cantharidin was NOT statistically significantly better than placebo over 2 months 4
- Other studies are retrospective, observational, or open-label with highly variable clearance rates (15.4-100%) 5
- A 2017 pediatric guideline noted that cantharidin showed "improvement greater than placebo but not statistically significant" 6
Requires In-Office Application
Cantharidin must be applied by a healthcare provider, requiring:
- Multiple office visits (typically every 2-4 weeks)
- Increased healthcare costs and time burden
- Potential treatment delays due to scheduling
Comparable Adverse Effects
Cantharidin causes similar local reactions:
Recent FDA Approval Context
Cantharidin 0.7% (brand name Ycanth) was FDA-approved in 2024, but this came after berdazimer's approval and the evidence base remains limited to smaller studies 7.
Clinical Guidelines Support Active Treatment
Multiple ophthalmology guidelines (2019,2024) recommend active treatment for symptomatic molluscum contagiosum rather than watchful waiting, particularly when lesions cause conjunctivitis or keratitis 8, 9. Treatment options listed include:
- Incision and curettage
- Simple excision
- Excision and cautery
- Cryotherapy
However, these guidelines predate FDA approval of berdazimer gel and do not specifically address topical prescription medications 8.
Practical Treatment Algorithm
First-Line: Berdazimer Gel 10.3%
- Apply once daily to all MC lesions for up to 12 weeks 1
- Mix Tube A (berdazimer gel) with Tube B (hydrogel) immediately before application
- Apply thin layer, allow to dry 10 minutes
- Avoid swimming/bathing for 1 hour after application
- Reassess at 6 weeks: If ≥50% clearance, continue; if no response, consider alternative
Second-Line: Cantharidin 0.7% (In-Office)
- For patients who cannot tolerate berdazimer
- For patients preferring in-office treatment
- Apply every 2-4 weeks as needed
Third-Line: Physical Destruction
- Curettage, cryotherapy, or laser for resistant cases
- Consider for patients with very few lesions who prefer single-visit treatment
Special Populations
Pediatric patients ≥1 year: Berdazimer is safe and effective, with 96% of trial participants aged 2-17 years 1, 2
Immunocompromised patients: Both treatments may be less effective; consider more aggressive approaches or referral to dermatology 8
Periocular lesions: Avoid topical medications near eyes; consider referral to ophthalmology for physical removal 8
Common Pitfalls to Avoid
- Don't wait for spontaneous resolution in symptomatic patients—this can take months to years and increases transmission risk 8
- Don't apply berdazimer to eyes, mouth, vagina, or unaffected skin 1
- Don't continue berdazimer if severe local reactions persist >24 hours—this indicates allergic contact dermatitis 1
- Don't premix or store mixed berdazimer gel—mix immediately before each application 1